Your NMN/NAD⁺ Supplement Doesn't Work. Here's What Does.
Why the most popular longevity supplement raises a number on your blood test but not the thing you actually care about — and where the real leverage is.
TL;DR
NAD⁺ is a molecule every cell needs to turn food into energy. It declines with age, which is why it became a longevity obsession.
NMN and NAD⁺ supplements reliably raise NAD⁺ in your blood. That part is real and well documented.
But that's mostly NAD⁺ inside your blood cells — not in the muscle, brain, and organs that matter. When researchers actually biopsied muscle, the supplements often didn't raise NAD⁺ there, and most trials showed no improvement in strength, blood sugar, or cholesterol versus placebo.
The reason: your cells, especially your mitochondria, tightly guard their own NAD⁺ with gates and recycling systems. Dumping in more raw material doesn't help if the gate is closed and the bucket is leaking.
What actually works: exercise (by a wide margin), good sleep, lowering chronic inflammation, and staying metabolically healthy. A short list of targeted supplements (urolithin A) and one newly approved drug (for a rare disease) aim at the real bottleneck instead of the raw material.
Bottom line: NMN isn't a scam, it's just the least important lever, and probably the last one worth your money. The gym beats the bottle.
This article is educational and not a substitute for individualized medical care. Decisions about supplements, peptides, or medications should be made with your own clinician.
The promise: one thing precursors definitely do
The pitch is seductive and partly true. NAD⁺ (nicotinamide adenine dinucleotide) is the central cofactor for cellular energy metabolism, for the sirtuin "longevity" enzymes, and for DNA-repair enzymes. Tissue NAD⁺ falls with age in animal models, and restoring it rejuvenates aged mice. So the logic goes: take a precursor — NMN (nicotinamide mononucleotide) or NR (nicotinamide riboside) — rebuild your NAD⁺, and slow the clock.
And precursors do one thing reliably: they raise the NAD⁺ you can measure in blood. Head-to-head human data show NMN and NR roughly double circulating NAD⁺ after about two weeks of supplementation. Multiple randomized, placebo-controlled trials confirm the rise. Short-term, the supplements are well tolerated, and as of September 2025 the FDA reversed its earlier position and confirmed NMN can be sold lawfully as a dietary supplement in the U.S.
So far, so good. The problem is everything after the blood test.
The catch: NAD+ in the blood does not benefit the cell
Two things break the story.
First, the clinical outcomes mostly aren't there. When you pool the human trials, the picture is sobering. One 2024 meta-analysis of twelve randomized trials (513 participants) found that NMN reliably raised blood NAD⁺ but produced no significant change in most clinically relevant outcomes. The authors went as far as to say the field may be overstating the benefits, noting that most of the underlying studies carried meaningful risk of bias. A separate 2024 meta-analysis (eight trials, 342 adults) found no significant benefit on fasting glucose, insulin, HbA1c, insulin resistance, or lipids. The positive signals that do exist — small gains in gait speed or grip strength in older men, a non-significant trend toward reduced arterial stiffness — are weak and have not replicated robustly.
Second, and more damning: the supplement often doesn't reach the tissue. This is the part the marketing never mentions. The "circulating NAD⁺" measured in these trials is overwhelmingly NAD⁺ inside blood cells — a convenient proxy, not the NAD⁺ in your quadriceps or your hippocampus. And when researchers took the harder step of biopsying skeletal muscle, the proxy fell apart:
A six-week trial of NR found no change in muscle NAD⁺ content at all, even though turnover markers rose.
A trial combining NR with pterostilbene tripled NAD⁺ in whole blood but not in skeletal muscle.
A week-long NR study likewise failed to raise muscle NAD⁺, raising only downstream breakdown products.
The one study that did show a rise in the aged-muscle NAD⁺ metabolome found that the functional readouts — mitochondrial respiration, mitochondrial content, protein acetylation — didn't budge.
In other words: the causal chain that's supposed to deliver benefit — precursor → blood NAD⁺ → tissue NAD⁺ → better mitochondrial and sirtuin function → clinical benefit — is solid at the first link and broken at the rest. The supplement "works" at exactly one step: the one on your lab report.
Why Doesn’t it Stay in the Cell? The Gate and the Leaky Bucket
To understand why more substrate doesn't fix the problem, you have to look at how cells actually manage NAD⁺. Two features dominate.
The gate. NAD⁺ doesn't drift freely into compartments. Mitochondria — where much of the aging-relevant action happens — hold their own NAD⁺ pool, imported through a dedicated transporter called SLC25A51, identified only in 2020. This gate is not a passive hole. Recent work shows it pulls NAD⁺ into the matrix against a steep electrochemical gradient, and it can only do so when the mitochondrial membrane potential is healthy. Let that potential collapse — as happens in damaged, aged mitochondria — and NAD⁺ actually leaks back out of the matrix. The transporter also depends on cardiolipin, the signature inner-membrane lipid that gets oxidized and depleted in dysfunctional mitochondria. The cruel irony: the sick mitochondria that most need NAD⁺ are precisely the ones least able to import and hold it. Substrate isn't the limiting factor — the gate is.
The leaky bucket. NAD⁺ levels reflect a balance of synthesis and consumption, and aging tilts the balance toward consumption. The chief culprit is CD38, an NAD⁺-consuming enzyme that rises with age — driven not by your tissues themselves but by the accumulation of inflammatory immune cells as part of "inflammaging," fueled in turn by senescent cells. CD38 doesn't just drain NAD⁺; it degrades NMN directly in the extracellular space, blunting the very supplement you swallowed before it can do anything. Knock out CD38 in mice and they're protected from age-related NAD⁺ decline; inhibit it pharmacologically and aged mice live longer and perform better. The drain, not the supply, is doing much of the damage.
So the honest model is a bucket with a leak and a gated lid. Pouring in more water (precursor) does little when the lid is shut (low membrane potential, oxidized cardiolipin) and the bucket is leaking (CD38, inflammation). Supplementation addresses the one input that usually isn't rate-limiting.
What actually moves the needle
Here is the same evidence, turned into action. Grades: A = strong human trial evidence; B = human but limited or mixed; C = mechanistic or preclinical; D = theoretical or early.
1. Exercise: Still the only proven way to raise muscle NAD⁺ (Grade A)
This is the headline, and it's not close. The enzyme that limits NAD⁺ recycling, NAMPT, declines with age — and training reverses that decline. Twelve weeks of aerobic or resistance training raised muscle NAMPT by 12–30% in both young and older adults, and aerobic fitness (VO₂peak) is the single best predictor of how much NAMPT you carry. More to the point: a ten-week resistance-training program actually raised the muscle NAD⁺ pool itself, alongside markers of new mitochondrial growth — doing exactly what the supplements failed to do. Exercise pulls three levers at once: it builds recycling capacity, it builds more mitochondria, and it preserves the membrane potential that keeps the gate open. If you do one thing on this list, do this one.
2. Protect the gate and the bucket (Grade B–C)
Sleep and circadian rhythm. The NAD⁺ salvage pathway is clock-controlled and oscillates daily; chronic circadian disruption suppresses it. Underrated and free.
Lower chronic inflammation and senescent-cell burden. This is upstream of CD38 — the more inflammatory load you carry, the wider the leak. General anti-inflammatory living (and, speculatively, future senolytic therapies) protects NAD⁺ by closing the drain.
Stay metabolically healthy and go easy on alcohol. Obesity and type 2 diabetes lower muscle NAMPT; alcohol consumes NAD⁺ directly during its metabolism.
Caloric restriction / time-restricted eating. Activates AMPK and sirtuins with strong mechanistic support, though direct human NAD⁺ data are thinner than the exercise data.
3. A short list of supplements that target the right problem (Grade A–C)
Urolithin A (e.g., Mitopure) — Grade A/B. This is the supplement with the best evidence, and notably it works on a different lever: it activates mitophagy, the cellular recycling of damaged mitochondria — improving the quality of the pool rather than adding raw material. Human trials show ~12% gains in muscle strength, meaningful improvements in endurance and walking tests, lower markers of mitochondrial inefficiency and inflammation, and increased mitophagy gene expression in muscle. Not miraculous (several trials missed their primary endpoint), but real — and a logical complement to, not a duplicate of, precursors. Worth knowing: most people can't make urolithin A from food (pomegranate, walnuts, berries) because they lack the necessary gut microbes, which is why a supplement is more reliable.
NR / NMN — Grade A for the biomarker, weak for outcomes. If you take them, take them on top of the foundation above, with realistic expectations: you're topping off the substrate, the least limiting link.
CoQ10/ubiquinol, PQQ, acetyl-L-carnitine, alpha-lipoic acid — Grade B/C. Mitochondrial cofactors with mixed human data; most convincing in deficiency states rather than as universal boosters.
4. Peptides and drugs (Grade A for one narrow use → D for longevity)
Elamipretide (SS-31 / Forzinity) — Grade A for Barth syndrome only. This is the most mechanistically elegant agent on the list: a cardiolipin-binding peptide that stabilizes cristae structure and the membrane potential — targeting the gate directly. In September 2025 it became the first FDA-approved mitochondria-targeted therapeutic, but for a single ultra-rare disease (Barth syndrome). Its broad trials in heart failure and primary mitochondrial myopathy failed. So: the mechanism is validated and now drug-approved, but any anti-aging use is off-label and unproven — a hypothesis, not a recommendation, and something to approach only under specialist supervision.
MOTS-c, humanin — Grade C/D. Mitochondrial-derived peptides with intriguing preclinical profiles and essentially no human data on tissue NAD⁺. Investigational.
Metformin, senolytics, CD38 inhibitors — Grade B–C/D. Each plausibly touches the synthesis-or-consumption balance, but none has human evidence specifically for raising mitochondrial NAD⁺.
A sane hierarchy
Ranked by evidence times mechanistic directness:
Exercise (aerobic + resistance) — the foundation; the only proven mover of tissue NAD⁺.
Protect the gate and quality — sleep, circadian rhythm, lower inflammation, urolithin A for mitophagy.
Reduce the drain — anti-inflammatory living; senolytics as the speculative extension.
Add substrate (NR/NMN) — cheap, low-risk, and last. It's the icing, not the cake.
Targeted drugs/peptides — promising mechanisms, but currently a bet rather than a conclusion outside their approved uses.
The honest takeaway
Here's a hypothesis worth holding loosely: the people with high tissue NAD⁺ are largely the people who are already fit and metabolically healthy — and high NAD⁺ may be more a readout of mitochondrial fitness than a lever you can pull from the supplement side. That would explain the central paradox of this field: NAD⁺ tracks beautifully with health and longevity, yet pouring in precursors doesn't reproduce the benefit. You can't supplement your way to the metabolic profile of someone who trains.
None of this means NMN is harmful or fraudulent — it's safe in the short term and it does what it says at the level of a blood draw. It just isn't the thing that's going to change your trajectory. The interventions that do raise tissue NAD⁺ and improve mitochondrial function are, annoyingly, the same ones we've always recommended: move your body, sleep, stay lean, and keep inflammation down. The bottle is optional. The behaviors are not.
Selected references
Sources are described in the author's own words; full citations can be retrieved via PubMed or the linked journals.
Igarashi et al. npj Aging (2022) — 12-week RCT of 250 mg/day NMN in older men; raised blood NAD⁺, with nominal gains in gait speed and grip strength.
Long-term NMN RCT, Scientific Reports (2023) — 12 weeks, middle-aged adults; raised serum nicotinamide with a non-significant trend toward reduced arterial stiffness.
Systematic review and meta-analysis, Critical Reviews in Food Science and Nutrition (2024) — 12 RCTs, 513 participants; NMN raised blood NAD⁺ but most clinical outcomes were unchanged; authors flagged possible overstatement of benefits and notable risk of bias.
Chen et al. Current Diabetes Reports (2024) — meta-analysis of 8 RCTs (342 adults); no significant benefit of NMN on glucose or lipid metabolism.
Remie et al. American Journal of Clinical Nutrition (2020) — 6-week NR; no change in skeletal-muscle NAD⁺ content.
Elhassan et al. Cell Reports (2019) — NR raised the aged-muscle NAD⁺ metabolome without changing mitochondrial respiration, content, or protein acetylation.
Reviews of NR muscle studies (e.g., Journals of Gerontology Series A, 2023; Science Advances, 2023) — multiple trials show blood NAD⁺ rises while skeletal-muscle NAD⁺ does not.
Luongo et al. Nature (2020) — identification of SLC25A51 (MCART1) as the mammalian mitochondrial NAD⁺ transporter.
Mitochondrial NAD⁺ import and membrane potential, Science Advances (2025) — membrane potential sustains matrix NAD⁺ import; its loss allows NAD⁺ to leak out.
SLC25A51 regulation, EMBO reports and Biochemical Society Transactions (2023) — cardiolipin binding and multitiered regulation of the transporter.
Camacho-Pereira et al. Cell Metabolism (2016) — CD38 drives age-related NAD⁺ decline; CD38-knockout mice are protected.
Chini lab, PNAS Nexus / FASEB (2020) — CD38 on immune cells degrades NMN extracellularly, blunting NMN-driven NAD⁺ boosting.
Peclat et al. Aging Cell (2022) — the CD38 inhibitor 78c extended lifespan and improved healthspan in aged mice.
Costford et al. Am J Physiol Endocrinol Metab (2010); and the 2019 Physiological Reports training study — exercise induces and restores skeletal-muscle NAMPT (12–30% increases).
Resistance-training study, Aging (2020) — training raised muscle NAD⁺ and NADH, NAMPT, sirtuin activity, and mitochondrial-biogenesis markers.
Singh et al. Cell Reports Medicine (2022) and Liu et al. JAMA Network Open (2022) — randomized trials of urolithin A showing improved muscle strength and endurance and better mitochondrial biomarkers.
Stealth BioTherapeutics / FDA (September 19, 2025) — accelerated approval of elamipretide (Forzinity) for Barth syndrome, the first FDA-approved mitochondria-targeted therapeutic.